Download PDF
Thromb Haemost 1999; 81(01): 96-103
DOI: 10.1055/s-0037-1614425
Review Article
Schattauer GmbH

Monocyte Plasminogen Activator Inhibitor 2 (PAI-2) Inhibits u-PA-mediated Fibrin Clot Lysis and Is Cross-linked to Fibrin

Helen Ritchie
1   From the Departments of Molecular and Cell Biology and, University of Aberdeen, Aberdeen, UK
,
Linda A. Robbie
1   From the Departments of Molecular and Cell Biology and, University of Aberdeen, Aberdeen, UK
2   From the Departments of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
,
Seonag Kinghorn
1   From the Departments of Molecular and Cell Biology and, University of Aberdeen, Aberdeen, UK
,
Rachel Exley
1   From the Departments of Molecular and Cell Biology and, University of Aberdeen, Aberdeen, UK
,
Nuala A. Booth
1   From the Departments of Molecular and Cell Biology and, University of Aberdeen, Aberdeen, UK
› Author Affiliations
Further Information

Publication History

Received29 June 1998

Accepted after revision22 September 1998

Publication Date:
08 December 2017 (online)

   Permissions and Reprints

Summary

Plasminogen activator inhibitor 2 (PAI-2) is a major product of activated human monocytes. Here we show that monocytes inhibited u-PA- but not t-PA-mediated fibrinolysis, by secreting PAI-2 into an overlying fibrin clot. Extracts of arterial and venous human thrombi were found to contain active PAI-2. PAI-2 was cross-linked to fibrin in a reaction catalyzed by two major transglutaminases (TG), tissue TG and factor XIII. The activity of PAI-2 was not affected by such cross-linking. Cross-linking of PAI-2 to fibrin was inhibited by Tridegin, a specific inhibitor of TG, and also by EDTA and iodoacetamide. The use of competitive peptides mimicking the loop between helices C and D of PAI-2 identified Gln 83 and 86 as residues important in cross-linking. This study defines a mechanism by which PAI-2 is localized to fibrin, where it acts as an effective inhibitor of u-PA-mediated fibrinolysis.

 

  • References

  • 1 Booth NA. Natural inhibitors of fibrinolysis. In: Haemostasis and Thrombosis.. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. 3rd edn. Churchill Livingstone; 1994: pp 699-717.
    Google Scholar
  • 2 Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994; 73: 1-19.
    CrossrefPubMedGoogle Scholar
  • 3 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
    CrossrefPubMedGoogle Scholar
  • 4 Lupu F, Heim D, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-100.
    CrossrefPubMedGoogle Scholar
  • 5 Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-45.
    CrossrefPubMedGoogle Scholar
  • 6 Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 75: 127-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Robbie LA, Wright GA, Booth NA, Bennett B. Inhibitors of fibrinolysis in normal and diseased human arteries. Thromb Haemost 1997; Suppl PS-2277 (abstr)
    PubMedGoogle Scholar
  • 8 Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachman F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460-8.
    PubMedGoogle Scholar
  • 9 Lyon S-G, iordano B, Loskutoff D, Chen C-S, Lazurus G, Keeton M, Jensen PJ. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochem 1994; 101: 105-12.
    CrossrefPubMedGoogle Scholar
  • 10 Whawell SA, Vipond MN, Scott-Combes DM, Thompson JN. Plasminogen activator inhibitor 2 reduces peritoneal activity in inflammation. Br J Surg 1993; 80: 107-9.
    CrossrefPubMedGoogle Scholar
  • 11 Astedt B, Hagerstrand I, Lecander I. Cellular localization in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986; 56: 63-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
    PubMedGoogle Scholar
  • 13 Remold O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett 1995; 315: 105-8.
    PubMedGoogle Scholar
  • 14 Zoellner H, Wojta J, Gallicchio M, McGrath K, Hamilton JA. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Thromb Haemost 1993; 69: 135-40.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Pytel BA, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor. J Cell Physiol 1990; 144: 416-22.
    CrossrefPubMedGoogle Scholar
  • 16 Ritchie H, Jamieson A, Booth NA. Thrombin modulates synthesis of plasminogen activator inhibitor 2 (PAI-2) by human peripheral blood monocytes. Blood 1995; 86: 3428-35.
    PubMedGoogle Scholar
  • 17 Ritchie H, Booth NA. Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-Golgi-independent pathway. Exp Cell Res 1998; 242: 439-50.
    CrossrefPubMedGoogle Scholar
  • 18 Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989; 74: 1396-1402.
    PubMedGoogle Scholar
  • 19 Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
    PubMedGoogle Scholar
  • 20 Gan H, Newman GW, Remold HG. Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. J Immunol 1995; 155: 1304-15.
    PubMedGoogle Scholar
  • 21 Dickinson JL, Bates EJ, Ferrante A, Antalis T. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor α-induced apoptosis. J Biol Chem 1995; 270: 27894-904.
    CrossrefPubMedGoogle Scholar
  • 22 Jensen PH, Schuler E, Woodrow G, Richardson M, Goss N, Hujrup P, Petersen TE, Rasmussen LK. A unique interhelical insertion in plasmino-gen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cro-linking. J Biol Chem 1994; 269: 15394-8.
    PubMedGoogle Scholar
  • 23 Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIatransglutaminase-catalyzed cross linking to cellular and extracellular structures. Eur J Biochem 1993; 214: 141-6.
    CrossrefPubMedGoogle Scholar
  • 24 Jensen PJ, Wu Q, Janowitz P Ando Y, Schechter NM. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 1995; 217: 65-72.
    CrossrefPubMedGoogle Scholar
  • 25 Aeschlimann D, Paulsson M. Transglutaminases: protein cro-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-15.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Gorman JJ, Folk JE. Structural features of glutamine substrates for tranS-glutaminases. J Biol Chem 1981; 256: 2712-6.
    PubMedGoogle Scholar
  • 27 Sakata Y, Aoki N. Significance of cro-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
    CrossrefPubMedGoogle Scholar
  • 28 Greenberg CS, Achyuthan KE, Borowitz MJ, Shuman MA. The transglutaminase in vascular cells and tissues could provide an alternative pathway for fibrin stabilization. Blood 1987; 70: 702-8.
    PubMedGoogle Scholar
  • 29 Robbie LA, Booth NA, Croll AM, Bennett B. The roles of α2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from endothelial cells. Purification and partial characterization. Eur J Biochem 1987; 165: 595-600.
    CrossrefPubMedGoogle Scholar
  • 31 Sancho ES, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli . Eur J Biochem 1994; 224: 125-31.
    CrossrefPubMedGoogle Scholar
  • 32 Steven J, Cottingham IR, Berry SJ, Chinery SA, Goodey AR, Courtney M, Ballance DJ. Purification and characterisation of plasminogen activator inhibitor 2 produced in Saccharomyces cerevisiae . Eur J Biochem 1991; 196: 431-8.
    CrossrefPubMedGoogle Scholar
  • 33 Reith A, Bennett B, Booth NA. Plasminogen activator inhibitor (PAI-2) in pregnancy plasma and ovarian cysts, studied by zymography after non denaturing gel electrophoresis. Fibrinolysis 1989; 3: 159-63.
    PubMedGoogle Scholar
  • 34 Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood sucking leech, Haementeria ghilianii. . Biochem J 1997; 324: 797-805.
    CrossrefPubMedGoogle Scholar
  • 35 Raut S, Gaffney P. Evaluation of the fibrin binding profile of two anti-fibrin monoclonal antibodies. Thromb Haemost 1996; 76: 56-64.
    PubMedGoogle Scholar
  • 36 Ritchie H, Jamieson A, Booth NA. Regulation, location and activity of plasminogen activator inhibitor 2 (PAI-2) in peripheral blood monocytes, macrophages and foam cells. Thromb Haemost 1997; 77: 1168-73.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Leung K-C, Byatt JA, Stephens RW. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (Minactivin). Thromb Res 1987; 46: 755-66.
    CrossrefPubMedGoogle Scholar
  • 38 Lijnen HR, Bachmann F, Collen D, Ellis V, Pannekoek H, Rijken DC, Thorsen S. Mechanisms of plasminogen activation. J Int Med 1994; 236: 415-20.
    CrossrefPubMedGoogle Scholar
  • 39 Ellis V, Pyke C, Eriksen J, Solberg H, Dano K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992; 13-8.
    PubMedGoogle Scholar
  • 40 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
    CrossrefPubMedGoogle Scholar
  • 41 Hettasch JM, Haroon ZA, Lai TS, Slaughter TF, Greenberg CS. Tissue transglutaminase as a wound healing enzyme that triggers platelet activation. Thromb Haemost 1997; Suppl PS-1439 (abstr)
    PubMedGoogle Scholar
  • 42 Tamaki T, Aoki N. Cro-linking of α2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
    PubMedGoogle Scholar
  • 43 Gruther MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9: 2361-5.
    PubMedGoogle Scholar
  • 44 Seale L, Finney S, Sawyer RT, Wallis RB. Tridegin, a novel inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis. Thromb Haemost 1997; 77: 959-63.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Genton C, Kruithof EKO, Schleuning W-D. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in human U937 lymphoma cells. J Cell Biol 1987; 104: 705-12.
    CrossrefPubMedGoogle Scholar
  • 46 Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-6.
    CrossrefPubMedGoogle Scholar